TAK Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

15.770

Open

15.770

VWAP

15.64

Vol

2.44M

Mkt Cap

49.39B

Low

15.515

Amount

38.20M

EV/EBITDA(TTM)

14.08

Total Shares

3.16B

EV

12.10T

EV/OCF(TTM)

13.15

P/S(TTM)

1.72

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.

Show More

Events Timeline

(ET)

2026-06-15

13:00:00

Takeda Presents Oveporexton Results Improving Narcolepsy Symptoms

2026-06-11 (ET)

2026-06-11

07:30:00

Takeda Reports Positive Phase 3 Results for Zasocitinib

2026-06-09 (ET)

2026-06-09

16:40:00

Takeda Launches New Drug in the U.S.

2026-05-31 (ET)

2026-05-31

20:50:00

Innovent Biologics Announces Preliminary Results of IBI363 Clinical Study

2026-05-18 (ET)

2026-05-18

16:20:00

Stocks Open Mixed as Rising Oil Prices Raise Concerns

2026-05-18

15:30:00

U.S. Jury Rules Takeda to Pay $885M in Damages

2026-05-18

14:40:00

U.S. Court Finds Takeda Pharmaceuticals Liable for Antitrust Violations

2026-05-18

14:30:00

Takeda Ordered to Pay Hundreds of Millions in Antitrust Case

2026-05-15 (ET)

2026-05-15

10:00:00

Trump Says China Will Purchase 200 Boeing Jets

2026-05-14 (ET)

2026-05-14

14:20:00

Takeda Pharmaceuticals Agrees to Pay $13.67M to Settle Healthcare Fraud Allegations

News

NASDAQ.COM

06-19NASDAQ.COM

Denali Sells Rare Pediatric Disease Priority Review Voucher for $195 Million

NASDAQ.COM

06-16NASDAQ.COM

Takeda Reports New Data on Oveporexton for Type 1 Narcolepsy

NASDAQ.COM

06-16NASDAQ.COM

Takeda Unveils New Narcolepsy Drug Study Results

Newsfilter

06-15Newsfilter

Takeda Presents Oveporexton Study Results at SLEEP 2026

seekingalpha

06-11seekingalpha

Takeda's Zasocitinib Outperforms Rival in Psoriasis Trial

Newsfilter

06-11Newsfilter

Zasocitinib Shows Superiority in Psoriasis Study

1 Analyst Rating

Wall Street analysts forecast TAK stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

18.00

Averages

18.00

High

18.00

Current: 0.000

Low

18.00

Averages

18.00

High

18.00

Bernstein

Market Perform

to

Outperform

upgrade

AI Analysis

2026-04-08

Reason

Bernstein

Price Target

AI Analysis

2026-04-08

upgrade

Market Perform

to

Outperform

Reason

Bernstein upgraded Takeda to Outperform from Market Perform with a price target of 6,900 yen, up from 5,100 yen, citing \"bold\" cost cuts and multiple upcoming de-risking events for the pipeline.

H.C. Wainwright

H.C. Wainwright

Buy

maintain

$97

2025-12-30

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$97

2025-12-30

maintain

Buy

Reason

H.C. Wainwright says Xoma (XOMA) took "a nice ride down the creativity road again with nice pipeline expansion," after the company announced an expanded relationship with partner Takeda (TAK). The deal with Takeda is highlighted by no cash out from Xoma for bringing in nine assets, the firm notes. This was accomplished by only marginally reducing Xoma's royalty/milestone share in Takeda's mezagitamab. Wainwright maintains its positive view here on the depth and breadth of Xoma's partnered assets as well as the ongoing creativity of transaction the company consummates, and looks forward to a transactional and royalty growing 2026. The firm has a Buy rating on Xoma with a price target of $97 on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TAK

Unlock Now

Valuation Metrics

The current forward P/E ratio for Takeda Pharmaceutical Co Ltd (TAK.N) is 9.88, compared to its 5-year average forward P/E of 26.24. For a more detailed relative valuation and DCF analysis to assess Takeda Pharmaceutical Co Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

26.24

Current PE

9.88

Overvalued PE

39.73

Undervalued PE

12.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

8.86

Current EV/EBITDA

4.99

Overvalued EV/EBITDA

10.93

Undervalued EV/EBITDA

6.79

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

1.41

Current PS

0.01

Overvalued PS

1.89

Undervalued PS

0.94

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

top value stocks

Intellectia · 85 candidates

Market Cap Category: large, midCurrent Ratio: >= 1.00Pe Ttm: <= 15Ps Ratio: <= 3.00P/B Ratio: <= 3.00Return On Equity: >= 0.0%P Fcf Ratio: <= 15.00Free Cash Flow Ttm: >= 0

Ticker

Name

Market Cap$

BILL Holdings Inc

4.14B

Callaway Golf Co

3.19B

Axia Energia SA

26.97B

Ecopetrol SA

25.99B

KT Corp

10.20B

Transportadora de Gas del Sur SA

4.42B

top investment for cheap buy

Intellectia · 208 candidates

Market Cap: >= 300.00MPrice: <= $20.00Analyst Consensus: Moderate Buy, Strong BuyEps Ttm: >= 0Free Cash Flow Ttm: >= 0

Ticker

Name

Market Cap$

Sony Group Corp

116.85B

Itau Unibanco Holding SA

95.00B

Nokia Oyj

74.38B

Energy Transfer LP

68.60B

Takeda Pharmaceutical Co Ltd

52.51B

Huntington Bancshares Inc

33.71B

Intellectia · 1 candidates

Region: US

Ticker

Name

Market Cap$

Takeda Pharmaceutical Co Ltd

52.51B

insiders buying stocks

Intellectia · 1172 candidates

Market Cap: >= 1000.00MPrice: >= $5.00Quarterly Insider Trading Dollar Volume: >= 0Monthly Average Dollar Volume: >= 300,000

Ticker

Name

Market Cap$

Takeda Pharmaceutical Co Ltd

56.30B

Kaspi.kz AO

15.10B

Central Puerto SA

2.42B

Royal Bank of Canada

242.44B

Bank of New York Mellon Corp

88.88B

Taiwan Semiconductor Manufacturing Co Ltd

1.92T

large cap taht is basing

Intellectia · 14 candidates

Market Cap: >= 10.00BRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Month Price Change Pct: $-5.00 - $5.00Support Resistance Relationship: PriceAroundSupport

Ticker

Name

Market Cap$

Johnson & Johnson

574.36B

Amgen Inc

189.44B

Pfizer Inc

153.13B

Williams Companies Inc

88.95B

Warner Bros Discovery Inc

68.79B

Takeda Pharmaceutical Co Ltd

57.12B

what stocks to buy today by swing max

Intellectia · 30 candidates

Region: USPrice: $5.00 - $150.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Week Predict Return: >= 5.0%Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Bright Horizons Family Solutions Inc

4.21B

Greenlight Capital Re Ltd

563.79M

BRC Group Holdings Inc

214.47M

Box Inc

3.37B

Fortis Inc

29.71B

NetEase Inc

75.69B

ANY STOCK FROM 5 TO 20.00

Intellectia · 1059 candidates

Region: USPrice: $5.00 - $20.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Mitsubishi UFJ Financial Group Inc

202.67B

Banco Santander SA

185.79B

Mizuho Financial Group Inc

105.35B

Petroleo Brasileiro SA Petrobras

92.03B

Itau Unibanco Holding SA

91.41B

Nu Holdings Ltd

87.41B

us stock between $0.1 and $20

Intellectia · 2503 candidates

Price: $0.10 - $20.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Mitsubishi UFJ Financial Group Inc

206.98B

Banco Santander SA

178.90B

Mizuho Financial Group Inc

104.37B

Petroleo Brasileiro SA Petrobras

87.06B

Itau Unibanco Holding SA

86.67B

Nu Holdings Ltd

83.54B

show stock below $20 and are marked bullish

Intellectia · 1002 candidates

Price: <= $20.00Option Sentiments: Bullish

Ticker

Name

Market Cap$

Lloyds Banking Group PLC

81.38B

Energy Transfer LP

60.60B

Takeda Pharmaceutical Co Ltd

51.17B

Banco Santander Brasil SA

50.00B

ASE Technology Holding Co Ltd

41.24B

Nokia Oyj

35.71B

acciones por debajo 20 dolares

Intellectia · 3008 candidates

Price: <= $20.00

Ticker

Name

Market Cap$

Mitsubishi UFJ Financial Group Inc

206.98B

Banco Santander SA

178.90B

Mizuho Financial Group Inc

104.37B

Petroleo Brasileiro SA Petrobras

87.06B

Itau Unibanco Holding SA

86.67B

Nu Holdings Ltd

83.54B

Whales Holding TAK

Trading Trends

People Also Watch

Frequently Asked Questions

What is Takeda Pharmaceutical Co Ltd (TAK) stock price today?

The current price of TAK is 15.63 USD — it has increased 1.36

What is Takeda Pharmaceutical Co Ltd (TAK)'s business?

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.

What is the price predicton of TAK Stock?

Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Takeda Pharmaceutical Co Ltd (TAK)'s revenue for the last quarter?

Takeda Pharmaceutical Co Ltd revenue for the last quarter amounts to 1.09T USD, increased 3.91

What is Takeda Pharmaceutical Co Ltd (TAK)'s earnings per share (EPS) for the last quarter?

Takeda Pharmaceutical Co Ltd. EPS for the last quarter amounts to -15.40 USD, decreased -76.42

How many employees does Takeda Pharmaceutical Co Ltd (TAK). have?

Takeda Pharmaceutical Co Ltd (TAK) has 47029 emplpoyees as of June 21 2026.

What is Takeda Pharmaceutical Co Ltd (TAK) market cap?

Today TAK has the market capitalization of 49.39B USD.